Breaking Finance News

PROMETIC LIFE SCIE COM NPV (NASDAQ:PFSCF) has been downgraded to Hold in a statement by Zacks Investment Research earlier today.

Boasting a price of $2.19, PROMETIC LIFE SCIE COM NPV (NASDAQ:PFSCF) traded 0.00% even on the day. With the last stock price close down -6.02% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. PROMETIC LIFE SCIE COM NPV has recorded a 50-day average of $2.23 and a two hundred day average of $2.33. Volume of trade was down over the average, with 0 shares of PFSCF changing hands under the typical 36,540

Zacks Investment Research has downgraded PROMETIC LIFE SCIE COM NPV (NASDAQ:PFSCF) to Hold in a statement released on 10/12/2016.

Performance Chart

PROMETIC LIFE SCIE COM NPV (NASDAQ:PFSCF)

With a total market value of $0, PROMETIC LIFE SCIE COM NPV has with a one year low of $1.29 and a one year high of $2.77 .

Brief Synopsis About PROMETIC LIFE SCIE COM NPV (NASDAQ:PFSCF)

ProMetic Life Sciences Inc., a biopharmaceutical company, develops bio separations, plasma-derived therapeutics, and small-molecule drugs. The company offers its technology platform for large-scale drug purification, drug development, proteomics, and the elimination of pathogens; and develops small molecule therapeutic products targeting unmet medical needs in the fields of fibrosis, autoimmune disease/inflammation, and cancer. It operates in two segments, Small Molecule Therapeutics and Protein Technology. The Small Molecule Therapeutics segmentÂ’s lead product candidate is PBI-4050, which targets unmet medical needs, such as the treatment of fibrosis in patients with chronic kidney diseases and certain cancers, and the side effects associated with chemotherapy. The Protein Technology segment provides Plasma Protein Purification System, a solution for plasma fractionation, as well as for the extraction and purification of therapeutic proteins from human plasma; bioseparation products based on applications of its patented Mimetic Ligand technology; and prion capture/pathogen removal technology platform that improves the safety profile of blood products and blood-derived therapeutics. The company was formerly known as Innovon Life Sciences Holdings Limited and changed its name to ProMetic Life Sciences Inc. in May 1998. ProMetic Life Sciences Inc. was founded in 1992 and is headquartered in Laval, Canada.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *